Bevacizumab is a recombinant anti-VEGF monoclonal antibody and is approved alone or in combination with chemotherapy for treatment of CRC, NSCLC, glioblastoma, cervical, ovarian, and renal cell cancers [22–26]. This evidence concerns the gene VEGFA and colorectal carcinoma.